학술논문
Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status
Document Type
Article
Author
Source
Annals of Allergy, Asthma & Immunology; March 2024, Vol. 132 Issue: 3 p355-362.e1
Subject
Language
ISSN
10811206
Abstract
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) often have atopic comorbidities, including elevated IgE levels and comorbid asthma. Omalizumab, an IgE monoclonal antibody, is an effective treatment for CRSwNP, but the impact of allergy or asthma status on response to omalizumab in patients with CRSwNP has not been well studied.